Publications by authors named "H Bugger"
Renal sympathetic denervation (RDN) is an interventional supplement to medical treatment in patients with arterial hypertension. While the first sham-controlled trial, SYMPLICITY HTN‑3 was neutral, with improved procedural details, patient selection and follow-up, recent randomized sham-controlled trials of second-generation devices show a consistent blood pressure lowering effect of RDN, as compared to sham controls. These new data and the recent U.
View Article and Find Full Text PDFArticle Synopsis
- * In the first trial (RCT-I), there were no significant differences in important health outcomes like cardiovascular mortality or stroke, while the second trial (RCT-II) showed a benefit in responder patients using shunts over a sham treatment.
- * The atrial shunt treatment in responders led to fewer heart failure events and better health-related quality of life measured by KCCQ, but also had a higher rate of ischemic stroke and reduced worsening kidney dysfunction compared to sham treatment.
Background: The myocardium adapts to ischemia/reperfusion (I/R) by changes in gene expression, determining the cardiac response to reperfusion. mRNA translation is a key component of gene expression. It is largely unknown how regulation of mRNA translation contributes to cardiac gene expression and inflammation in response to reperfusion and whether it can be targeted to mitigate I/R injury.
View Article and Find Full Text PDFArticle Synopsis
- The study aims to understand the immune cell composition in human atherosclerotic plaques, which differs significantly from what is observed in mouse models, often used for research.
- Single-cell RNA sequencing was employed to reveal a diverse immune cell landscape in human plaques, primarily consisting of T-cells, highlighting activation and memory formation that aren't adequately represented in mice.
- The findings suggest that traditional mouse models may not effectively translate to human atherosclerosis, particularly regarding activated T-cell responses, posing questions about their relevance in studying adaptive immune cell behavior.
Article Synopsis
- Short-QT-syndrome type 1 (SQT1) is a heart condition caused by a genetic change that affects how the heart's electrical system works, leading to a higher risk of serious heart problems.
- In a study with rabbits that have SQT1, researchers found that giving them a substance called L-Carnitine helped lengthen the time it takes for the heart to reset after beating, which is a good thing for heart health.
- The study suggests that L-Carnitine works by improving the way certain electrical currents in the heart function, which might help people with this condition in the future.